Profectus BioSciences, Inc., a Baltimore, MD-based developer of therapeutic and preventive vaccines against infectious diseases and cancers, has received a $5.4m grant.
The funding, awarded under the Partnerships for Biodefense RFA The Partnerships for Biodefense RFA, by the Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, will support the preclinical development of m102.4, an antibody intended as a post-exposure prophylactic against Nipah or Hendra virus infection.
Profectus is developing this antibody in collaboration with Dr. Christopher Broder (USU), and Dr. Thomas Geisbert (Galveston National Laboratory, University of Texas Medical Branch, Galveston). The company is also partnering with Catalent Pharma Solutions (Middleton, WI) to access their proprietary GPEx® technology to produce high yield mammalian cell lines for cGMP production of m102.4.
Established in 2003, Profectus BioSciences is a technology based vaccine company focused on the treatment and prevention of chronic viral diseases, including Hepatitis C Virus (HCV), Human Papilloma Virus (HPV), Herpes Simplex Virus type 2 (HSV-2), and Human Immunodeficiency Virus (HIV), and Malaria and Ebola and Marburg viruses.